Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 12/20 | 0.53 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.53 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
| ▸ | CTRC | Q99895 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL1406326 | 0.86 | GPR132 (0.56) | GPR132CMKLR2CMKLR1LMNAECE1 | |
| SCHEMBL2344285 | 0.86 | PSMB5 (0.60) | GPR132PSMB5 | |
| Leucine SCHEMBL3816604 | 0.83 | GPR132 (0.53) | GPR132CMKLR2CMKLR1LMNAECE1 | |
| SCHEMBL234157 | 0.83 | PSMB5 (0.54) | GPR132CMKLR2CMKLR1LMNAECE1 | |
| SCHEMBL2229201 | 0.82 | GPR132 (0.69) | GPR132CMKLR2CMKLR1LMNAECE1 | |
| SCHEMBL30037998 | 0.82 | GPR132 (0.69) | GPR132CMKLR2CMKLR1LMNAECE1 | |
| SCHEMBL3497405 | 0.82 | GPR132 (0.69) | GPR132CMKLR2CMKLR1LMNAECE1 | |
| SCHEMBL2228194 | 0.78 | LMNA (0.57) | GPR132LMNAECE1 | |
| SCHEMBL9828179 | 0.78 | LMNA (0.57) | GPR132LMNAECE1 | |
| SCHEMBL2336223 | 0.77 | ACE (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100036159-A1 | Peptide boronic acid inhibitors | PAION DEUTSCHLAND GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| US-20060084592-A1 | Peptide boronic acid inhibitors | TRIGEN LIMITED | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084592-A1 | Peptide boronic acid inhibitors | BMX, YBX1, HAX1 | GPR132 4454/4885CMKLR2 1219/4885CMKLR1 1033/4885 |
| US-20100036159-A1 | Peptide boronic acid inhibitors | BMX, YBX1, HAX1 | GPR132 4437/4885CMKLR2 1170/4885CMKLR1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.